210 related articles for article (PubMed ID: 16129674)
1. An activin-A/C chimera exhibits activin and myostatin antagonistic properties.
Muenster U; Harrison CA; Donaldson C; Vale W; Fischer WH
J Biol Chem; 2005 Nov; 280(44):36626-32. PubMed ID: 16129674
[TBL] [Abstract][Full Text] [Related]
2. An activin mutant with disrupted ALK4 binding blocks signaling via type II receptors.
Harrison CA; Gray PC; Fischer WH; Donaldson C; Choe S; Vale W
J Biol Chem; 2004 Jul; 279(27):28036-44. PubMed ID: 15123686
[TBL] [Abstract][Full Text] [Related]
3. Activin A/bone morphogenetic protein (BMP) chimeras exhibit BMP-like activity and antagonize activin and myostatin.
Korupolu RV; Muenster U; Read JD; Vale W; Fischer WH
J Biol Chem; 2008 Feb; 283(7):3782-90. PubMed ID: 18056265
[TBL] [Abstract][Full Text] [Related]
4. Identification of a functional binding site for activin on the type I receptor ALK4.
Harrison CA; Gray PC; Koerber SC; Fischer W; Vale W
J Biol Chem; 2003 Jun; 278(23):21129-35. PubMed ID: 12665502
[TBL] [Abstract][Full Text] [Related]
5. Residues in the C-terminal region of activin A determine specificity for follistatin and type II receptor binding.
Fischer WH; Park M; Donaldson C; Wiater E; Vaughan J; Bilezikjian LM; Vale W
J Endocrinol; 2003 Jan; 176(1):61-8. PubMed ID: 12525250
[TBL] [Abstract][Full Text] [Related]
6. Activin-A binds follistatin and type II receptors through overlapping binding sites: generation of mutants with isolated binding activities.
Harrison CA; Chan KL; Robertson DM
Endocrinology; 2006 Jun; 147(6):2744-53. PubMed ID: 16527838
[TBL] [Abstract][Full Text] [Related]
7. Cripto forms a complex with activin and type II activin receptors and can block activin signaling.
Gray PC; Harrison CA; Vale W
Proc Natl Acad Sci U S A; 2003 Apr; 100(9):5193-8. PubMed ID: 12682303
[TBL] [Abstract][Full Text] [Related]
8. Activins bind and signal via bone morphogenetic protein receptor type II (BMPR2) in immortalized gonadotrope-like cells.
Rejon CA; Hancock MA; Li YN; Thompson TB; Hébert TE; Bernard DJ
Cell Signal; 2013 Dec; 25(12):2717-26. PubMed ID: 24018044
[TBL] [Abstract][Full Text] [Related]
9. Effect of adenovirus-mediated overexpression of follistatin and extracellular domain of activin receptor type II on gonadotropin secretion in vitro and in vivo.
Leal AM; Takabe K; Wang L; Donaldson CJ; MacConell LA; Bilezikjian LM; Verma IM; Vale W
Endocrinology; 2002 Mar; 143(3):964-9. PubMed ID: 11861519
[TBL] [Abstract][Full Text] [Related]
10. The structure of the follistatin:activin complex reveals antagonism of both type I and type II receptor binding.
Thompson TB; Lerch TF; Cook RW; Woodruff TK; Jardetzky TS
Dev Cell; 2005 Oct; 9(4):535-43. PubMed ID: 16198295
[TBL] [Abstract][Full Text] [Related]
11. Differential antagonism of activin, myostatin and growth and differentiation factor 11 by wild-type and mutant follistatin.
Schneyer AL; Sidis Y; Gulati A; Sun JL; Keutmann H; Krasney PA
Endocrinology; 2008 Sep; 149(9):4589-95. PubMed ID: 18535106
[TBL] [Abstract][Full Text] [Related]
12. Osteogenic protein-1 binds to activin type II receptors and induces certain activin-like effects.
Yamashita H; ten Dijke P; Huylebroeck D; Sampath TK; Andries M; Smith JC; Heldin CH; Miyazono K
J Cell Biol; 1995 Jul; 130(1):217-26. PubMed ID: 7790373
[TBL] [Abstract][Full Text] [Related]
13. Biological activity of follistatin isoforms and follistatin-like-3 is dependent on differential cell surface binding and specificity for activin, myostatin, and bone morphogenetic proteins.
Sidis Y; Mukherjee A; Keutmann H; Delbaere A; Sadatsuki M; Schneyer A
Endocrinology; 2006 Jul; 147(7):3586-97. PubMed ID: 16627583
[TBL] [Abstract][Full Text] [Related]
14. Regulation and actions of Smad7 in the modulation of activin, inhibin, and transforming growth factor-beta signaling in anterior pituitary cells.
Bilezikjian LM; Corrigan AZ; Blount AL; Chen Y; Vale WW
Endocrinology; 2001 Mar; 142(3):1065-72. PubMed ID: 11181520
[TBL] [Abstract][Full Text] [Related]
15. Transforming Growth Factor-β Family Ligands Can Function as Antagonists by Competing for Type II Receptor Binding.
Aykul S; Martinez-Hackert E
J Biol Chem; 2016 May; 291(20):10792-804. PubMed ID: 26961869
[TBL] [Abstract][Full Text] [Related]
16. Cripto is a noncompetitive activin antagonist that forms analogous signaling complexes with activin and nodal.
Kelber JA; Shani G; Booker EC; Vale WW; Gray PC
J Biol Chem; 2008 Feb; 283(8):4490-500. PubMed ID: 18089557
[TBL] [Abstract][Full Text] [Related]
17. Purification of recombinant activin A using the second follistatin domain of follistatin-related gene (FLRG).
Arai KY; Tsuchida K; Li C; Watanabe G; Sugino H; Taya K; Nishiyama T
Protein Expr Purif; 2006 Sep; 49(1):78-82. PubMed ID: 16737827
[TBL] [Abstract][Full Text] [Related]
18. Growth differentiation factor-9 signaling is mediated by the type I receptor, activin receptor-like kinase 5.
Mazerbourg S; Klein C; Roh J; Kaivo-Oja N; Mottershead DG; Korchynskyi O; Ritvos O; Hsueh AJ
Mol Endocrinol; 2004 Mar; 18(3):653-65. PubMed ID: 14684852
[TBL] [Abstract][Full Text] [Related]
19. Proteomic identification and functional validation of activins and bone morphogenetic protein 11 as candidate novel muscle mass regulators.
Souza TA; Chen X; Guo Y; Sava P; Zhang J; Hill JJ; Yaworsky PJ; Qiu Y
Mol Endocrinol; 2008 Dec; 22(12):2689-702. PubMed ID: 18927237
[TBL] [Abstract][Full Text] [Related]
20. Spatial expression patterns of activin and its signaling system in the zebrafish ovarian follicle: evidence for paracrine action of activin on the oocytes.
Wang Y; Ge W
Biol Reprod; 2003 Dec; 69(6):1998-2006. PubMed ID: 12930712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
